Aging
Navigate
Research Paper|Volume 11, Issue 5|pp 1501—1509

Curcumin inhibits liver metastasis of gastric cancer through reducing circulating tumor cells

Xixi Gu1, Qiqi Zhang1, Wei Zhang2, Liang Zhu2
  • 1Department of Integrative Medicine, Zhongshan Hospital, University of Fudan, Shanghai 200032, China
  • 2Department of Interventional Therapy, Zhongshan Hospital, University of Fudan, Shanghai 200032, China
Received: January 26, 2019Accepted: February 23, 2019Published: March 7, 2019

Copyright: © 2019 Gu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Primary gastric cancer (PGC) is the fourth most common malignant human cancer and the second leading cause of death worldwide. The majority of the subjects of PGC is diagnosed at a late stage, resulting in poor prognosis and therapeutic outcome, largely attributable to dissemination of tumor cells into circulation as circulating tumor cells (CTCs) and their formation of distal tumor. Curcumin is an active ingredient from the rhizome of the plant Curcuma longa. Here, we assessed whether treatment with Curcumin may reduce the incidence of metastatic tumor formation in liver in mice carrying PGC. We found that Curcumin treatment significantly reduced the presence of CTCs and formation of liver tumor. Mechanistically, Curcumin reduced CXCR4 expression in PGCs in vitro and in vivo, and thus likely inhibited metastasis of PGC through suppression of stromal cell -derived factor-1/CXCR4 signaling. Thus, our study suggests that Curcumin may inhibit liver metastasis of PGC through reducing CTCs.